HRK and cancer: TP53 inhibits or activates anti-apoptotic factors (BCL-2, BCL-2-XL, BCL-2-XW, and MCL-1) [19] or pro-apoptotic effectors (BAX, BAK, BID, BIM, BIK, BMF, BIF-1, BAD, NOXA, and HRK) [20,21,22] through the DBD domain and Hippo pathway, respectively, and promotes the apoptosis of cancer cells.